Moderna, Inc. (MRNA) · Nov 6, 2026 · Earnings

Moderna earnings beat big as 2026 revenue outlook jumps

Beat — Q3 revenue $1.313B vs approximately $0.89B consensus

Moderna’s earnings sharply beat expectations as COVID sales drove a revenue surge and management raised 2026 growth guidance.

Moderna is transitioning from a COVID-heavy business toward a broader respiratory and oncology portfolio while cutting spending and preserving cash. The prior setup already called for a seasonally strong third quarter and up to 10% full-year revenue growth, but the published Q3 consensus was roughly $0.89 billion of revenue, with analysts expecting a loss; the quarter landed far above that bar.

The quarter was a clear operating beat, not just a narrative win. Revenue reached $1.313 billion, up 29% year over year, versus approximately $0.89 billion of published consensus, while diluted EPS was $0.38 versus a year-ago loss of $0.51. The upside was driven primarily by higher international COVID vaccine sales and government-partnership deliveries, so it validates near-term commercial execution but does not yet prove that the newer flu, RSV or oncology products are carrying the business. 〔0〕

Q3 2026Q3 2025External / prior
Total revenue (Financial results)$1.313B (+29%)$1.016B~$0.89B consensus
Diluted EPS (Financial results)$0.38$(0.51)
R&D expense (Financial results)$583M (-27%)$801M
FY26 revenue growth (Outlook)15%-25%Up to 10% prior outlook
FY26 R&D expense (Outlook)$2.7B~$2.9B prior outlook
Year-end cash and investments (Outlook)$8.1B-$8.3B$4.7B-$5.2B prior outlook

Management materially raised the business outlook. Full-year revenue growth is now expected at 15%-25%, versus the previous ceiling of 10%, while planned R&D falls to about $2.7 billion from $2.9 billion. That combination is better than the market was prepared for and strengthens the near-term transition story.

The balance-sheet improvement is real but partly financing-driven. Moderna ended September with $8.0 billion of cash and investments, and raised its year-end outlook to $8.1-$8.3 billion, but the quarter’s improvement relied heavily on approximately $2.6 billion of net convertible-note proceeds. That gives the company more room to fund oncology and meet debt obligations, yet it also adds leverage and means the cash upgrade is not solely the result of self-funded operations.

The pipeline adds support, but the quarter is still mainly a respiratory-sales story. Intismeran’s positive melanoma Phase 3 data strengthen Moderna’s longer-term diversification case, while the norovirus program failed to meet the early-success bar and will not add a cohort this season. The oncology opportunity is therefore advancing, but it remains dependent on regulatory submissions and eventual commercialization rather than current revenue.

Bottom line: This is a substantial beat that improves Moderna’s near-term revenue and cost-control story, with guidance raised well beyond the prior framework. It matters because execution exceeded a low bar by a wide margin, though the upside remains concentrated in seasonal COVID demand and partly supported by new debt financing.

What to watch next

Intismeran regulatory submissions and additional pipeline readouts

Original filing on SEC EDGAR

More Moderna, Inc. news

Moderna earnings beat big as 2026 revenue outlook jumps | MRNA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.